Uptake of Automated Insulin Delivery Systems: Costs and Insurance Reimbursement by Zickler, Michael

 2 





 Automated Insulin Delivery Systems .................................................................................4 
 Three Generations ...............................................................................................................5 











 Cost Considerations...........................................................................................................12 
 Factors for Insurance Reimbursement ..............................................................................13 
 
Discussion......................................................................................................................................15 
 Cost Considerations...........................................................................................................15 











Objective: In the next few years, many advances are expected in automated insulin delivery 
systems for patients with diabetes. However, these technologies will be expensive. With this, 
many questions surround the uptake of automated insulin delivery systems. This study examines 
the cost considerations for the uptake of these devices and the most important factors influencing 
insurance coverage from key stakeholder perspectives. 
 
Methods: This is a qualitative study based on interviews with individuals representing a diabetes 
professional organization, a device company and patients (Type 1 diabetics). Codes were 
assigned to interview responses, which were grouped by specific aim and stakeholder. A data 
matrix was used to identify reoccurring themes and patterns among stakeholders. 
 
Results: The main themes related to cost considerations were costs vs. benefits and complexity 
of the devices. The main factors influencing insurance coverage were a focus on short term 
outcomes, total cost of care for diabetics, an absence of research / data and upfront cost barriers 
for automated insulin delivery. 
 
Conclusions: To increase uptake of automated insulin delivery systems, my findings indicate the  
need to improve the technology largely by simplifying and reducing the complexity of the 
devices. Processes also need to be simplified for obtaining the device and securing ongoing 
supplies. Lastly, additional research is needed to show that automated insulin delivery is 
effective at improving outcomes for a broader range of Type 1 diabetics to support more 
extensive insurance coverage.  
 4 
Background 
Automated Insulin Delivery Systems 
Individuals with Type 1 diabetes do not produce insulin, a necessary pancreatic hormone 
to break down glucose in the blood. These individuals require exogenous insulin to maintain 
normal blood glucose levels and avoid major complications (e.g., amputation, stroke, blindness).  
However, having the right amount of insulin to maintain normal blood glucose levels is 
challenging. Automated insulin delivery systems can help achieve normal blood glucose levels 
by automatically delivering insulin based on an individual’s blood glucose concentration. Early 
clinical trials and studies have shown that automated insulin delivery systems are effective at 
reducing A1c (measure of blood glucose), increasing the amount of time an individual is in a 
desired blood glucose range, and reducing hypoglycemia and hyperglycemia events (DeVries, 
2017). 
Automated insulin delivery 
systems have three main 
components (Figure 1): a 
continuous glucose monitoring 
(CGM) system, an insulin pump 
and a control algorithm (Trevitt, 
Simpson, & Wood, 2016, p. 714). 
A CGM system monitors an 
individual’s blood glucose level in 
real time and sends the blood glucose information to the individual’s insulin pump and the digital 
controller which uses an algorithm to calculate the amount of insulin required based on the 
Figure 1: Illustration of an automated insulin delivery system 
(“Artificial Pancreas,” n.d.). 
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CGM’s readings. Lastly, the insulin pump, which stores insulin, delivers the calculated amount 
of required insulin through an infusion site attached to the user (Trevitt, Simpson, & Wood, 
2016, p. 714).  
CGMs and insulin pumps have both start-up and ongoing costs. Current CGMs in 
automated insulin delivery systems have two components: a sensor placed on the skin and a 
battery powered, wireless enabled transmitter attached to the sensor above the skin to transmit 
blood glucose values (Christel, 2014). The sensor requires weekly changes, while the transmitter 
has a lifespan of about three months (Christel, 2014). For the insulin pump, the infusion site 
requires a change every three days and the insulin cartridge needs to be refilled as needed 
(Christel, 2014). The estimated retail cost per month for an automated insulin delivery system for 
these supplies is $1,000 (Christel, 2014). These costs allow device companies to maintain 
continual revenue flow beyond the initial purchase of an automated insulin delivery system. 
 
Three Generations 
Figure 2: The three developmental generations of automated insulin delivery systems (Trevitt, 
Simpson, & Wood, 2016, p. 715). 
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There are three generations of automated insulin delivery systems, with each successive 
generation requiring less user input (Figure 2) (Trevitt, Simpson, & Wood, 2016, p. 715). The 
first generation, which minimizes hypoglycemia (low blood glucose) and hyperglycemia (high 
blood glucose), has been on the market since 2014 (Trevitt, Simpson, & Wood, 2016, p. 715; 
Scheiner, 2014).  
In mid-2017, first generation automated insulin delivery systems will be succeeded by 
second generation devices, which have an increased amount of control over insulin delivery and 
dosage from the device. The second generation devices consist of two stages. The first stage 
automatically increases or decreases insulin delivery depending on a computer algorithm that 
predicts the person’s blood glucose level (Trevitt, Simpson, & Wood, 2016, p. 715). These 
devices “deliver a variable rate of insulin 24 hours a day based on the personalized needs of the 
individual, maximizing the time glucose levels are within the target range. It is designed to learn 
what an individual’s insulin needs are and to take action to minimize both high and low glucose 
levels (Hakami, 2016).” However, individuals still need a manual bolus of insulin at mealtimes 
based on their carbohydrate consumption. These devices are termed “hybrid closed loop 
systems” because the loop of insulin delivery is not completely reliant on the device’s algorithm 
(Trevitt, Simpson, & Wood, 2016, p. 715). Examples of devices of this stage are the Medtronic 
670G, which is expected to launch in July 2017 (Hakami, 2016) and a system being developed 
by Bigfoot Biomedical which is currently in clinical trials and expected to launch in 2018 / 2019 
(Cahill, 2016).   
The second stage—a fully-closed loop system—addresses the delay between insulin 
injection and absorption into the body (Weinzimer et al., 2008, p. 938). As stated by Bally, 
Thabit, & Hovorka (2017), “Manual meal-time announcement and prandial insulin boluses are 
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still recommended to be carried out by the user to overcome the delay in insulin action profile of 
currently available insulin analogues.” In fully-closed loop systems, user input for meals is not 
required and insulin delivery is completely reliant on the device’s algorithm (Trevitt, Simpson, & 
Wood, 2016, p. 715). As of 2015, eighteen fully-closed loop systems were in development 
(Trevitt, Simpson, & Wood, 2016, p. 717). However, these systems will not be available until 
faster acting insulin is developed to overcome the current delay between insulin injection and 
absorption into the body to break down consumed sugars.  
The third generation of automated insulin delivery systems mimics the human pancreas. 
These fully-closed loop systems can deliver multiple hormones that are usually delivered by 
properly functioning human pancreases (Trevitt, Simpson, & Wood, 2016, p. 715). Systems in 
development utilize insulin and glucagon (a pancreatic hormone that increases blood glucose 
when low) (“The Artificial,” 2016). However, artificial glucagon has a very short shelf life and is 
not approved by the United States Food and Drug Administration (FDA).   
 
Current Insurance Coverage 
Insurance coverage policies for automated insulin delivery systems in the first stage of 
the second generation, such as the Medtronic 670G, are developing. Automated insulin delivery 
systems are a secondary option to multiple daily injections (MDI) of insulin or traditional insulin 
infusion pumps. In this tiered approach, patients must start with a less expensive option; this is 
analogous to coverage of brand name drugs when a generic alternative is available. The general 
design of insurance reimbursement is a large upfront cost to cover the purchase of an automated 
insulin delivery device. With an estimated price around $9,000, a beneficiary with 20% 
coinsurance would need to pay $1,800 upfront to begin on a system (Belluz, 2016). Additionally, 
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automated insulin delivery and insulin pumps are typically covered by a four-year warranty after 
the original purchase (Medical Coverage, 2017). Health insurers will not cover another device 
within the four-year window (Medical Coverage, 2017). 
In November 2016, Blue Cross Blue Shield (BCBS) released its coverage policy for automated 
insulin delivery devices (“Artificial Pancreas Device,” 2016). Aetna followed in March 2017 and 
Cigna a month later in April (Infusion Pumps, 2017; Diabetes Tests, 2017; Medical Coverage, 
2017). Kaiser Foundation Health Plan reviewed its coverage for automated insulin delivery 
devices in October 2016 (Clinical Review, 2016). United Healthcare is expected to cover 
automated insulin delivery systems similar to standard insulin pumps through its exclusive 
partnership with Medtronic, which began in July 2016 (Brown & Close, 2016). For beneficiaries 
ages 18 and older, Medtronic devices are the “preferred in-network, durable medical equipment 
provider” for insulin pumps and automatic insulin delivery devices (Brown & Close, 2016). 
Table 1 shows the insurance coverage policies for BCBS and Aetna. UnitedHealthcare, Cigna 
and Kaiser Foundation Health Plan have similar policies to Aetna (Brown & Close, 2016; 
Infusion Pumps, 2017; Diabetes Tests, 2017; Medical Coverage, 2017). While this is the current 
coverage for automated insulin delivery systems, specifically the Medtronic 670G, it is subject to 




Organization Automated Insulin Delivery Coverage 
Blue Cross Blue Shield 
(all subsidiaries) 
Beneficiary must meet all the following requirements: 
• Age 16 or older 
• Have an A1c value between 5.8% and 10.0% 
• Have previously used an insulin pump for more than 6 
months 
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• Have at least 2 documented nocturnal hypoglycemic events 
in a 2-week period 
Aetna Beneficiary must meet all the following requirements: 
• Have been on a program of multiple daily injections of 
insulin with frequent self-adjustments of insulin dose for at 
least 6 months prior 
• Have completed a comprehensive diabetes education 
program 
• Have documented frequency of glucose self-testing an 
average of at least 4 times per day during the prior 2 
months 
• Meet at least one of the following criteria while on MDI: 
o Dawn phenomenon with fasting blood sugars 
frequently exceeding 200 mg/dL 
o HbA1c greater than 7.0% 
o History of recurring hypoglycemia (less than 60 
mg/dL) 
o History of severe glycemic excursions 




A recent Health Affairs article projected the expected savings to Medicare for covering 
automated insulin delivery systems for beneficiaries with Type 1 diabetes to be $937 million 
over 25 years (O’Grady, John, & Winn, 2012, p. 1822). Although automated insulin delivery 
systems hold great potential for reducing the burden of diabetes, the initial and ongoing costs of 
this technology, especially with limited reimbursement by payers, may limit their uptake. This 
study obtained stakeholder perspectives on costs which may limit the widespread use of these 
devices. The findings can be used by stakeholders to make decisions about insurance coverage 
and uptake of these devices. 
 
Table 1: Automated insulin delivery system coverage policies for BCBS and Aetna (“Artificial 
Pancreas Device,” 2016; Infusion Pumps, 2017; Diabetes Tests, 2017). 
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Specific Aims 
There are two specific aims: 
1. Identify the cost considerations that are most critical for stakeholders (diabetes 
professional organization, device company, insurer, patients) in the uptake of automated 
insulin delivery systems.  
2. Identify the factors that each stakeholder reports as most important for influencing 




This was a qualitative study of the perspectives of major stakeholders related to the 
uptake of automated insulin delivery: a diabetes professional organization, an automated insulin 
delivery system device development company, insurance company, and patients. After 
identifying potential participants through websites of respective stakeholder organizations, 
individuals were contacted by email inviting voluntary participation in the study. All interviews 
followed a script specifically tailored to each stakeholder group. The interviews examined issues 
related to the costs associated with the uptake of automated insulin delivery systems, current and 
future insurance reimbursement of the devices, factors influencing insurance reimbursement, 
relationships among the various stakeholders, and how consumers will value automated insulin 
delivery. 
Two interviews were conducted with individuals representing a diabetes professional 
organization, one interview with an individual representing an automated insulin delivery system 
device development company and two interviews with Type 1 diabetics currently using a pump. 
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The two individuals from a diabetes professional organization represent the same company. Both 
individuals are involved in the research and development of automated insulin delivery systems 
and one is also involved in insurance reimbursement. The representative from the device 
company focuses on the financial and insurance reimbursement aspects of automated insulin 
delivery. Both patients are Type 1 diabetics and current pump users for several years and have 
experience with multiple different insulin pumps and diabetes technologies. An attempt was 
made to interview an individual from a health insurer, however, company policy would not allow 
participation in this study. All interviews were voice recorded to foster high-quality data 
collection and analysis. Notes were taken during the interviews to complement the recordings. 
 
Analysis 
Each interview was transcribed from the audio recording and supplemented by notes 
taken during the conversation. All transcripts were de-identified, except for type of stakeholder. 
The analysis focused on response elements related to either costs of automated insulin delivery 
uptake or insurance reimbursement of such devices. Responses were grouped by specific aim for 
each interview and codes were assigned to the applicable elements in each response. The 
investigator assigned codes based on categories displayed in table 2.  
Cost Considerations  Factors for Insurance Reimbursement 
1. Costs vs. Benefits 
a. Avoid Hypoglycemia 
b. Prevent Hyperglycemia 
c. Quality of Life 
2. Patient Preferences 
a. Adherence 
b. Expectations 
3. Need Simplification 




c. Total Cost of Care 
2. Lack of research to support 
reimbursement 
3. Insufficient cost effective information 
4. Durable medical equipment barriers 
5. Adherence leads to coverage 
Table 2: Preliminary codes 
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 To identify reoccurring themes and patterns in the data across stakeholders, a data matrix 
was created in which data from all stakeholder interviews were aggregated on the basis of 
specific aim and assigned data code. This data matrix mapped all meaningful responses into a 




Aim Main Themes Contains Following Preliminary Codes 
Cost Considerations 
Costs vs. Benefits 
• Avoid Hypoglycemia 
• Prevent Hyperglycemia 
• Quality of Life 
Complexity • Patient Preferences 
• Need Simplification 






Total Cost of Care • Total Cost of Care 
Data / Research • Lack of research to support reimbursement 
• Insufficient cost effective information 
Upfront Costs • Durable medical equipment barriers 
 
Cost Considerations 
The first theme to emerge was that the costs of the devices need to be weighed against the 
relative benefits. Automated insulin delivery will be more expensive than traditional insulin 
pumps, but there are also several potential benefits associated with these newer devices. For 
example, the systems can decrease A1c, help to avoid hypo and hyperglycemia incidents and 
increase the quality of life of Type 1 diabetics (which was particularly important for the 
diabetics). They would be willing to pay more for a quality of life benefit. As one Type 1 
Table 3: Main themes by aim and which preliminary codes each theme contains. 
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diabetic said, “It depends on the quality of life. Am I willing to pay more for a CGM? Yes. Does 
it improve my quality of life? Definitely.”  
Second, current automated insulin delivery systems are complex for patients, providers 
and device companies. To begin with, the devices are complicated for individuals to set up. To 
address this concern, device companies have a large support infrastructure to assist providers in 
order to start patients on their devices. For patients, the devices are confusing and challenging to 
use. They still require data input for meals, the software interfaces are not user friendly and they 
are bulky and take up a lot of ‘real estate’ on an individual’s body. According to a device 
company, current systems are “very costly and very burdensome for patients [...] when you add 
the cognitive burden trying to deal with all these devices, whether it be trying to get them to 
work correctly or trying to interpret data and graphs.” Similarly, an individual from a 
professional organization stated: “Right now, the devices will work and work well, but they are 
not convenient.” Also, current insurance reimbursement policies are complex and are hard to 
navigate in order to become eligible for reimbursement. The process to obtain the device 
supplies is also complicated. Some supplies may be purchased from the pharmacy, while others 
need to be ordered from a supplier. Additionally, the supplies have varying lifespans. For 
example, the CGM sensor needs to be replaced every seven days and the insulin pump infusion 
site needs to be replaced every three days.  
 
Factors for Insurance Reimbursement 
The first factor to emerge is that insurance coverage focuses on the short-term cost-
related outcomes, such as avoidable hospitalizations for hypoglycemia. As the representative 
from the device company mentioned, “This isn’t about long-term complications, this isn’t about 
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kidney failure, blindness, or macular diseases that can be associated with long term 
consequences. This is about annual costs per year.” While decreasing A1c has the greatest 
potential to reduce long term outcomes, according to the stakeholders, this long-term factor is 
less important than the short-term.  
The second factor is the total cost of care, which is related to the focus on short-term 
outcomes. Insurance coverage is influenced by the yearly total cost of care for beneficiaries with 
Type 1 diabetes. Although there are significant costs associated with automated insulin delivery 
systems (e.g., equipment, monthly supplies), there is potential for their costs to be offset by 
reducing avoidable diabetes-related emergency department (ED) visits and hospitalizations. An 
individual from the diabetes professional organization stated that insurance companies “are very 
interested in hypoglycemia because hypoglycemia for them is one of the biggest cost drivers 
because if you have severe hypoglycemia and end up in the hospital, that costs as much as the 
system for a couple years.” According to the device company, avoidable hospitalizations and ED 
visits for Type 1 diabetics costs the United States’ healthcare system $14 billion a year.  
The third factor influencing decisions related to insurance coverage of automated insulin 
delivery devices is the absence of data and research on the systems. Proof of cost effectiveness is 
important to support insurance coverage of automated insulin delivery. According to individuals 
representing a professional organization and a device company, cost effectiveness data are not 
available for current systems. The individual from the device company said, “These are 
expensive devices that, today, are not really known to deliver health economic outcomes.” 
Similarly, a representative from a diabetes professional organization expressed the possible cost 
effectiveness value of automated insulin delivery systems by stating that “if [the system] causes 
you to not have severe hypoglycemia and end up at the hospital, there is actually less cost overall 
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to the system […] that is a big value savings.” In addition, current clinical trials only use a 
narrow range of participants, thereby limiting generalizability of any findings.  
The fourth theme was around the large upfront cost for insurers and out-of-pocket costs 
for patients when they begin on a system. While insurers make an upfront investment in a 
system, the patient also faces costs, depending on their coinsurance. For patients, this cost may 
pose a barrier to start on automated insulin delivery. The device company expressed a desire to 
eliminate this barrier by spreading costs over a longer period of time to make the devices more 
affordable for Type 1 diabetics. A possible solution introduced is to have a monthly subscription 





There are several ways to influence the two main cost considerations of costs vs. benefits 
and the complexity of automated insulin delivery systems to increase uptake. First, these devices 
may be more expensive for individuals with Type 1 diabetes, but they also have great potential 
benefits (including reducing long-term costs). Device companies and providers will have to fully 
explain the benefits of automated insulin delivery to patients and insurers to justify increased 
costs to support wide uptake of devices. These benefits can include improved quality of life, 
fewer ED visits and hospitalization, and fewer diabetic complications.  
Second, the complexity and cognitive burden associated with automated insulin delivery 
is high. As noted earlier, the devices are complicated, bulky, and take up substantial space on an 
individual’s body. Professional organizations and device companies should make automated 
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insulin delivery systems smaller and easier to use. There are several potential approaches to 
reducing the complexity of automated insulin delivery devices.  A first step could be to switch 
the system’s controls from the insulin pump to the user’s cell phone. This is similar to recent 
CGM improvements. While pre-meal bolus inputs cannot be eliminated without faster acting 
insulin, other user inputs should be decreased. Lastly, the size of the insulin pump and CGM 
should be reduced to allow the devices to be less bulky and take up less ‘real estate’ on an 
individual’s body. A possible solution, as mentioned by an individual at the professional 
organization, would be to combine the insulin pump’s infusion site and CGM so that the user 
only has one piece of equipment attached to their body. 
Also contributing to the complexity is the process of obtaining device supplies. To 
simplify this process, device companies, providers and insurers should work to streamline the 
system to have all supplies come from one source with one prescription on a regular basis. This 
efficiency will decrease the costs associated with the current complexity in obtaining automated 
insulin delivery system supplies.  
 
Factors for Insurance Reimbursement 
The focus on short-term outcomes is worrisome and surprising. While the FDA focuses 
on reductions in A1c (correlating with a decrease in long-term complications) as an approval 
criterion, some stakeholders seem less concerned about the long-term benefits as a factor for 
insurance coverage. The rationale for this lack of concern may be related to the fact that long-
term outcomes have a lesser effect on private health insurers since most long-term complications 
occur when the individual is covered by a different insurer or on Medicare. In the future, there 
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should be an increased focus on the long-term to reduce expensive complications connected with 
elevated A1cs and poor glycemic control. 
There needs to be more research to show cost effectiveness and benefits to a wider range 
of Type 1 diabetics. Participants in earlier clinical studies had a decrease in hypoglycemic 
events, which should reduce avoidable hospitalizations. Notably, the average cost of an 
admission for hypoglycemia is $32,000 each. For device companies, the easiest path to insurance 
reimbursement is to show insurers that, even though these systems are more expensive at first, 
costs (especially short-term) will decrease. Cost effectiveness research should focus on this 
connection. 
Additionally, research studies should recruit a wider range of participants who may 
benefit from automated insulin delivery systems, for example, children and individuals with poor 
glycemic control and/or frequent diabetes-related ED visits and hospitalizations. With a wider 
range of patients, studies could show the specific groups of patients with Type 1 diabetes for 
whom automated insulin delivery systems are safe and effective. This could provide insurers 
with the evidence they need to cover this technology for these high-risk beneficiaries.  
Lastly, leasing a device may reduce a significant barrier—high upfront out-of-pocket 
costs of an automated insulin delivery system. However, this has some potential challenges. 
Currently, the user can keep the device after four years when they upgrade to a new device and 
they can switch to an old device if their new one breaks. With a leased automated insulin 
delivery system, the user will not own the device. This may cause the individual to lose access to 
the device in the future after the lease is over. Thereby, this would prohibit them from switching 
back to the device if a newer one breaks. A second issue arises if the individual loses insurance 
coverage. By losing insurance coverage, the individual also loses access to the automated insulin 
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delivery system. Currently, an individual losing insurance coverage still owns the device and can 
use it. By leasing the system, the individual would lose access to their insulin delivery method, 
forcing them to switch to a less advanced method, since these automated insulin delivery systems 
would be unaffordable to lease without insurance. 
 
Limitations 
There are several limitations to this study. First, the sample size was small and non-
representative, which limits generalizability. Future studies should use a larger, more 
representative sample of stakeholders. Moreover, this study is missing the perspective of a key 
stakeholder, a health insurance organization. Contacted organizations either declined to be 
interviewed or were not allowed to participate. Second, all coding was completed by a single 
person using his own judgment. A qualitative coding software could be used in the future. 
 
Conclusion 
Automated insulin delivery systems are rapidly changing as new generations are being 
developed. This qualitative study aimed to identify the cost considerations associated with the 
uptake of these devices and the most important factors influencing insurance coverage. Costs vs. 
benefits and complexity were the common cost considerations, while the factors important for 
influencing insurance coverage were a focus on short term outcomes, total cost of care for 
diabetics, a lack of research / data and upfront cost barriers for automated insulin delivery. 
Based on these findings, recommendations that may increase uptake of devices include: 
fully explaining the benefits of automated insulin delivery to patients; decreasing the complexity 
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and cognitive burden associated with using this technology; and simplifying the process to obtain 
device supplies by having all supplies come from one source on a regular basis. 
Recommendations for increasing insurance reimbursement include increasing focus on 
long term outcomes, emphasizing cost effectiveness research, including a wider range of 
participants in device clinical studies and reducing upfront cost barriers for patients through a 
possible monthly device lease. These recommendations are designed to increase insurance 
coverage of automated insulin delivery systems and, therefore, uptake of such devices. 
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